| Literature DB >> 36066627 |
Anouk T R Weemaes1,2, Matty P Weijenberg3, Antoine F Lenssen4,5, Milou Beelen6.
Abstract
PURPOSE: To describe changes in physical performance and patient-reported outcomes in cancer survivors who participated in an exercise program as part of usual-care multidisciplinary rehabilitation and the influence of training adaptations during the coronavirus-19 (COVID-19) pandemic.Entities:
Keywords: Aerobic capacity; Fatigue; Mental health; Muscle strength; Oncology; Quality of life
Year: 2022 PMID: 36066627 PMCID: PMC9444699 DOI: 10.1007/s00520-022-07351-5
Source DB: PubMed Journal: Support Care Cancer ISSN: 0941-4355 Impact factor: 3.359
Fig. 1Participant flowchart
Characteristics of cancer survivors who started multidisciplinary rehabilitation overall and according to starting the rehabilitation before or after the start of the COVID-19 pandemic
| Cancer survivors who participated in the original exercise program (Training frequency 2/wk) | Cancer survivors who participated in the adapted exercise program, since the COVID-19 pandemic (Training frequency 1/wk) | ||
|---|---|---|---|
| Sex ( | |||
| Male | 42 (22.7) | 27 (24.8) | 15 (19.7) |
| Female | 143 (77.3) | 82 (75.2) | 61 (80.3) |
| Age (years) | 55.7 ± 11.5 | 56.2 ± 11.0 | 54.9 ± 12.2 |
| Body height (cm) | 169.0 ± 7.9 | 169.2 ± 8.0 | 168.6 ± 7.9 |
| Body mass (kg) | 79.3 ± 14.4 | 79.0 ± 13.8 | 79.8 ± 15.3 |
| Body mass index (kg/m2) | 27.9 ± 5.3 | 27.6 ± 5.0 | 28.2 ± 5.8 |
| Cancer type ( | |||
| Breast cancer | 86 (46.5) | 51 (46.8) | 35 (46.1) |
| Lung cancer | 15 (8.1) | 10 (9.2) | 4 (5.3) |
| Colorectal cancer | 14 (7.6) | 8 (7.3) | 7 (9.2) |
| Lymphomas | 9 (4.9) | 5 (4.6) | 4 (5.3) |
| Leukemia | 9 (4.9) | 3 (2.8) | 6 (7.9) |
| Cervix | 9 (4.9) | 5 (4.6) | 4 (5.3) |
| Prostate | 7 (3.8) | 4 (3.9) | 3 (3.7) |
| Other | 36 (19.5) | 27 (24.8) | 16 (21.1) |
| Metastasis ( | |||
| Lymphatic metastasis | 38 (20.5) | 18 (16.5) | 20 (26.3) |
| Distant metastasis | 16 (8.6) | 11 (10.1) | 5 (6.6) |
| No metastasis | 131 (70.8) | 80 (73.4) | 51(67.1) |
| Treatment ( | |||
| Surgery | 138 (74.6) | 82 (75.2)) | 56 (73.7) |
| Chemotherapy | 121 (65.4) | 65 (59.6) | 56 (73.7) |
| Radiotherapy | 100 (54.1) | 47 (43.1) | 38 (50.0) |
| Hormone therapy | 57 (30.8) | 33 (30.3) | 24 31.5) |
| Immunotherapy | 25 (13.5) | 9 (8.3) | 16 (21.1) |
| Stem cell transplantation | 8 (4.3) | 3 (2.8) | 5 (6.6%) |
| Time since treatment (months) | 4.7 ± 4.4 | 4.9 ± 4.9 | 4.4 ± 3.6 |
| Comorbidity ( | |||
| Cardiovascular | 45 (24.3) | 20 (26.3) | 25 (22.9) |
| Respiratory | 15 (8.1) | 8 (7.3) | 7 (9.2) |
| Diabetes | 8 (4.3) | 6 (5.5) | 2 (2.6) |
Values are presented as n (%) for categorical variables and as mean ± SD for continuous variables
aSums of percentages are higher than 100% because participants received more than one type of treatment
bSums of percentages are less than 100% because not all participants were suffering from comorbidities
Participation of cancer survivors undergoing multidisciplinary rehabilitation in other interventions than the exercise intervention
| Other interventions ( | Cancer survivors who participated in the original exercise program (training frequency 2/wk) | Cancer survivors who participated in the adapted exercise program, since the COVID-19 pandemic (training frequency 1/wk) |
|---|---|---|
| Psychology | 58 (78.4) | 50 (80.6) |
| | ||
| Occupational therapy fatigue | 57 (77.0) | 42 (67.8) |
| | ||
| Occupational therapy return to work | 36 (48.7) | 32 (51.8) |
| | ||
| Dietetics | 12 (16.2) | 10 (16.1) |
| |
Data is presented only for participants that completed the exercise training
The frequency and percentage (n, %) of participants that were indicated for an intervention are presented. Of these participants that were indicated for the module, the frequency and percentage (n, %) of participants that completed the module at the end of the exercise program (T = 1) are presented
aNote that this was the status of completion of the intervention at T = 1 and that in many instances the interventions were still ongoing
2/wk, twice weekly; 1/wk, once weekly
Changes in mean outcomes of performance tests within groups and differences in changes in outcomes between the group of cancer survivors that participated in the original exercise program as part of multidisciplinary rehabilitation and the group of cancer survivors that participated in the adapted exercise program since COVID-19
| Cancer survivors who participated in the original exercise program (training frequency 2/wk) | Cancer survivors who participated in the adapted exercise program, since the COVID-19 pandemic (training frequency 1/wk) | Difference between groups ( | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| MCID a | T = 0 | T = 1 | Change absolute | % | 95% CI | T = 0 | T = 1 | Change absolute | % | 95% CI | Difference | 95% CI | |
| Aerobic capacity | |||||||||||
| CPET | |||||||||||
| VO2peak (mL/kg/min) [ | 1.0 | 19.8 ± 5.2 | 21.7 ± 6.2 | 1.9 † | 9.6% | 1.3–2.5* | 19.5 ± 6.0 | 20.9 ± 5.9 | 1.4 † | 7.2% | 0.8–1.9* | − 0.5 | − 0.3 to 1.3 |
| CPET WRpeak (W/kg) | N.A | 1.7 ± 0.6 | 1.9 ± 0.7 | 0.2 | 11.8% | 0.1–0.2* | 1.6 ± 0.6 | 1.7 ± 0.7 | 0.1 | 6.3% | 0.1–0.2* | − 0.1 | − 0.1 to 0.0 |
| | |||||||||||
| VO2 AT (mL/kg/min) | N.A | 11.7 ± 2.5 | 13.3 ± 3.3 | 1.6 | 13.7% | 1.1–2.2* | 12.1 ± 3.0 | 13.8 ± 3.4 | 1.6 | 13.2% | 1.1–2.2* | 0.0 | − 0.8 to 0.8 |
| OUES (/kg) | N.A | 22.7 ± 5.4 | 24.1 ± 6.1 | 1.4 | 6.2% | 0.7–2.1* | 22.5 ± 6.6 | 23.6 ± 6.3 | 1.2 | 5.3% | 0.4–1.9* | − 0.3 | − 1.3 to 0.7 |
| RCP reached b | 48 (44.4) | 36 (46.8 | |||||||||
| VO2 RCP (mL/kg/min) | N.A | 18.7 ± 4.3 | 20.8 ± 4.9 | 2.1 | 11.2% | 1.5–2.7* | 19.0 ± 5.4 | 20.5 ± 5.6 | 1.4 | 7.4% | 0.7–2.2* | − 0.7 | − 1.6 to 0.3 |
| SRT WRpeak (W/kg) [ | |||||||||||
| 0.26 | 3.12 ± 0.92 | 3.48 ± 0.96 | 0.36 † | 11.5% | 0.28–0.44* | 3.02 ± 0.88 | 3.25 ± 0.88 | 0.23 | 7.6% | 0.14–0.32* | − 0.13 | − 0.25 to − 0.02* | |
| 6-MWD (m) [ | |||||||||||
| 30.5 | 514 ± 104 | 577 ± 101 | 63 † | 12.3% | 51–75* | 515 ± 92 | 564 ± 104 | 49 † | 9.5% | 36–63* | − 14 | − 31 to 4 | |
| Muscle strength c | |||||||||||
| 1- RM leg press (kg) | N.A | 86.3 ± 22.8 | 118.6 ± 35.1 | 32.3 | 37.4% | 26.6–38.0* | 108.2 ± 29.2 | 137.0 ± 33.8 | 28.8 | 26.6% | 22.8–34.9* | − 3.2 |− 10.8% | − 12.3 to 5.8 |− 2.9% – 20.4% |
| 1-RM chest press (kg) [ | 6.25 | 24.1 ± 11.3 | 35.8 ± 14.6 | 11.7 † | 48.5% | 9.7 – 13.7* | 27.0 ± 11.2 | 32.7 ± 11.8 | 5.7 | 21.5% | 3.8 – 7.7* | − 6.0 |− 27.0% | − 8.7 to − 3.0* |− 50.2% to − 9.2%* |
Means ± SD were presented for both groups and changes within groups were calculated with corresponding 95% confidence intervals (CI). *Statistically significant, †Clinically relevant
Changes in outcomes were compared between both groups. Differences in change scores between groups were reported in the last column with 95% CI, corrected for baseline values, which were calculated using linear regression
aMinimally clinically important differences are provided when they have been determined and reported in previous studies, as described in the “Methods” section. References are provided in the first column of the table []. When MCIDs were not available in literature, this was reported as not available (N.A.)
bFrequencies and percentages of participants that reached RCP at both tests (T = 0 and T = 1) were reported, with corresponding values
cDifferences in change scores between groups, with corresponding 95% CI, are given in absolute numbers and | percentages, to account for baseline differences due to the usage of different exercise machines
CPET cardiopulmonary exercise test, VOpeak peak oxygen uptake, WRpeak peak work rate, RERpeak peak expiratory exchange rate, VO AT oxygen uptake at anaerobic threshold, VO RCP oxygen uptake at respiratory compensation point, OUES oxygen uptake efficiency slope, SRT steep ramp test, 6-MWT 6-min walking test, 1-RM one-repetition maximum. 2/wk twice weekly, 1/wk once weekly, MCID minimally clinically important difference, N.A. data not available
Changes in mean outcomes of patient-reported outcomes within groups and differences in changes in outcomes between the group of cancer survivors that participated in the original exercise program as part of multidisciplinary rehabilitation and the group of cancer survivors that participated in the adapted exercise program since COVID-19
| MCID | Cancer survivors who participated in the original exercise program (training frequency 2/wk) | Cancer survivors who participated in the adapted exercise program, since the COVID-19 pandemic (training frequency 1/wk) | Difference between groups ( | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| T = 0 | T = 1 | Change | 95% CI | T = 0 | T = 1 | Change | 95% CI | Difference | 95% CI | ||
| Quality of life | MCID a | ||||||||||
| (EORTC-QLQ-C30) [ | |||||||||||
| Global QoL | 10.0 | 56.86 ± 16.15 | 71.10 ± 16.09 | 14.24 † | 9.7–18.8* | 57.45 ± 16.23 | 68.79 ± 18.76 | 11.34 † | 6.6–16.1* | − 2.84 | − 8.63 to 2.95 |
| Physical functioning | 10.0 | 72.04 ± 15.59 | 83.83 ± 12.26 | 11.40 † | 8.2–14.6 * | 70.33 ± 18.67 | 83.83 ± 12.26 | 13.50 † | 8.8–18.2* | 1.45 | − 2.84 to 5.74 |
| Role functioning | 10.0 | 55.28 ± 25.00 | 70.43 ± 20.56 | 15.16 † | 9.4–20.9* | 52.13 ± 26.83 | 74.82 ± 22.75 | 22.70 † | 15.5–29.9* | 5.42 | − 1.57 to 12.41 |
| Emotional functioning | 10.0 | 63.98 ± 26.69 | 73.39 ± 23.80 | 9.40 | 3.7–15.0 * | 61.35 ± 21.73 | 78.55 ± 21.73 | 17.20 † | 11.0–23.4* | 6.42 | − 13.18 to 0.35 |
| Cognitive functioning | 10.0 | 62.26 ± 28.30 | 69.08 ± 25.93 | 6.80 | 0.9–12.7* | 62.41 ± 28.12 | 72.34 ± 23.90 | 9.93 | 3.7–16.2* | 3.17 | − 4.14 to 10.49 |
| Social functioning | 10.0 | 59.41 ± 24.82 | 79.04 ± 26.98 | 19.63 † | 12.7–26.5* | 62.06 ± 29.01 | 78.72 ± 22.44 | 16.67 † | 10.1–23.3* | − 1.62 | − 9.88 to 6.64 |
| Sum score functioning | 10.0 | 62.60 ± 17.86 | 75.07 ± 17.86 | 12.48 † | 8.5–16.5* | 61.65 ± 18.51 | 77.65 ± 14.84 | 16.00 † | 12.2–19.8 * | 3.14 | − 1.76 to 8.03 |
| Fatigue (MFI) [ | |||||||||||
| General fatigue | 3.18 | 16 ± 3 | 12 ± 4 | − 3 † | − 4 to − 3* | 16 ± 3 | 12. ± 4 | − 4 † | − 5 to − 3 * | 0 | − 2 to 1 |
| Physical fatigue | 3.45 | 16 ± 3 | 10 ± 4 | − 6 † | − 7 to − 4* | 15 ± 4 | 10 ± 5 | − 5 † | − 7 to − 4* | 0 | − 1 to 2 |
| Reduced motivation | 3.60 | 11 ± 4 | 9 ± 4 | − 2 | − 3 to − 2* | 12 ± 4 | 9 ± 4 | − 3 | − 4 to − 2* | 0 | − 1 to 1 |
| Reduced activity | 3.50 | 14 ± 4 | 11 ± 4 | − 3 | − 4 to − 2* | 14 ± 4 | 11 ± 4 | − 4 † | − 5 to − 3* | 0 | − 2 to 1 |
| Mental fatigue | 3.80 | 13 ± 4 | 12 ± 5 | − 1 | − 2 to 0* | 13 ± 5 | 12 ± 5 | − 1 | − 3 to 0* | 0 | − 2 to 1 |
| Sum score | 69 ± 15 | 54 ± 17 | − 15 | − 19 to − 12* | 71 ± 12 | 54 ± 17 | − 17 | − 22 to − 12* | − 1 | − 7 to 4 | |
| Anxiety and depression (HADS) [ | |||||||||||
| Anxiety | 1.7 | 8 ± 5 | 7 ± 4 | − 1 | − 2 to 0* | 9 ± 4 | 7 ± 4 | − 2 † | − 3 to − 1* | 0 | − 2 to 1 |
| Depression | 1.7 | 7 ± 5 | 5 ± 4 | − 2 † | − 3 to − 1* | 7 ± 4 | 5 ± 5 | − 2 † | − 3 to − 1* | 0 | − 1 to 2 |
| Sum score | N/A | 15 ± 9 | 12 ± 8 | − 4 | − 5 to − 2* | 16 ± 7 | 12 ± 8 | − 4 | − 6 to − 2* | 0 | − 2 to 2 |
Means ± SD were presented for both groups and changes within groups, with corresponding 95% confidence intervals (CI). *Statistically significant, †Clinically relevant
Changes in outcomes were compared between both groups. Differences in change scores between groups were reported in the last column with 95% CI, corrected for baseline values, which were calculated using linear regression. EORTC-QLQ-C30 European Organization for Research and Treatment for Cancer Quality of Life Questionnaire, MFI Multidimensional Fatigue Inventory, HADS Hospital Anxiety and Depression Score, 2/wk twice weekly, 1/wk once weekly
aMinimally clinically important differences are provided when they have been determined and reported in previous studies, as described in the “Methods” section. References are provided in the first column of the table []